NASDAQ:ADAG - Adagene Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.89
  • Forecasted Upside: 68.87 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.07
▼ -0.61 (-2.95%)

This chart shows the closing price for ADAG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adagene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADAG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADAG

Analyst Price Target is $33.89
▲ +68.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adagene in the last 3 months. The average price target is $33.89, with a high forecast of $40.57 and a low forecast of $29.00. The average price target represents a 68.87% upside from the last price of $20.07.

This chart shows the closing price for ADAG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Adagene.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2021Morgan StanleyLower Price TargetOverweight$34.00 ➝ $33.00High
6/25/2021China Renaissance SecuritiesInitiated CoverageBuy$40.57High
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$33.00High
3/8/2021Morgan StanleyInitiated CoverageOverweight$34.00High
3/5/2021The Goldman Sachs GroupInitiated CoverageBuy$29.00High
(Data available from 7/25/2016 forward)
Adagene logo
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China.
Read More

Today's Range

Now: $20.07
Low: $18.92
High: $20.79

50 Day Range

MA: $14.56
Low: $12.53
High: $20.68

52 Week Range

Now: $20.07
Low: $11.11
High: $31.83

Volume

173,084 shs

Average Volume

49,504 shs

Market Capitalization

$873.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Adagene?

The following Wall Street analysts have issued reports on Adagene in the last year: China Renaissance Securities Ltd., Jefferies Financial Group Inc., Morgan Stanley, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ADAG.

What is the current price target for Adagene?

4 Wall Street analysts have set twelve-month price targets for Adagene in the last year. Their average twelve-month price target is $33.89, suggesting a possible upside of 68.9%. China Renaissance Securities Ltd. has the highest price target set, predicting ADAG will reach $40.57 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $29.00 for Adagene in the next year.
View the latest price targets for ADAG.

What is the current consensus analyst rating for Adagene?

Adagene currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADAG will outperform the market and that investors should add to their positions of Adagene.
View the latest ratings for ADAG.

What other companies compete with Adagene?

How do I contact Adagene's investor relations team?

Adagene's physical mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The company's listed phone number is 86 512 8777 3632 and its investor relations email address is [email protected] The official website for Adagene is www.adagene.com.